TCGA-OR-A5JW-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.253
- BILE_ACID_METABOLISM+0.241
- ANDROGEN_RESPONSE+0.239
- PROTEIN_SECRETION+0.142
- TGF_BETA_SIGNALING+0.115
- WNT_BETA_CATENIN_SIGNALING+0.109
- NOTCH_SIGNALING+0.078
- ESTROGEN_RESPONSE_EARLY+0.070
- MITOTIC_SPINDLE+0.068
- HEDGEHOG_SIGNALING+0.066
Top 10 suppressed
- E2F_TARGETS-0.415
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.328
- G2M_CHECKPOINT-0.310
- DNA_REPAIR-0.299
- OXIDATIVE_PHOSPHORYLATION-0.293
- MYOGENESIS-0.292
- ALLOGRAFT_REJECTION-0.269
- APOPTOSIS-0.264
- MYC_TARGETS_V1-0.224
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3290 | Med | Medulloblastoma | 0.781 |
| 2 | MNG526 | — | — | 0.766 |
| 3 | TCGA-05-4396-01A-21R-1858-07 | — | cohortA3 | 0.756 |
| 4 | TCGA-E2-A15P-01A-11R-A115-07 | — | B | 0.752 |
| 5 | TCGA-OR-A5LL-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.749 |
| 6 | SRR1313106 | — | B | 0.748 |
| 7 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.746 |
| 8 | SRR27320668 | — | — | 0.743 |
| 9 | TCGA-C8-A1HE-01A-11R-A13Q-07 | — | B | 0.742 |
| 10 | TCGA-44-6147-01A-11R-A278-07 | — | cohortMD2 | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.253 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.241 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.239 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.142 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.115 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.109 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.078 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.068 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.066 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.043 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.042 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.027 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.014 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.011 | Inavolisib | — uncovered |